Status:
COMPLETED
Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer
Lead Sponsor:
Mansoura University
Conditions:
Breast Cancer Female
Breast Cancer Patients
Eligibility:
FEMALE
18-65 years
Phase:
PHASE2
Brief Summary
This clinical trial is a randomized clinical trial that aims to assess the usefulness of adding pentoxifylline to the neoadjuvant chemotherapy treatment protocol of doxorubicin/cyclophosphamide fllowe...
Eligibility Criteria
Inclusion
- Adult female patients \>18 years old with histologic confirmation of invasive breast cancer
- Planned to administer neoadjuvant chemotherapy protocol comprised of doxorubicin/ cyclophosphamide followed by paclitaxel (AC/T)
- Adequate hepatic, renal, and bone marrow functions
Exclusion
- Patients on a treatment regimen of phosphodiesterase inhibitors
- Patients who are taking antiplatelet or anticoagulant treatment
- Patients who are allergic to phosphodiesterase inhibitors
- History of recent hemorrhagic events
- Active peptic ulcer
- patients who have mouth or teeth problem.
Key Trial Info
Start Date :
December 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06186700
Start Date
December 25 2023
End Date
December 1 2024
Last Update
July 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Center of Mansoura University
Al Mansurah, Egypt